CACNA2D2

CACNA2D2
Identifiers
AliasesCACNA2D2, CACNA2D, calcium voltage-gated channel auxiliary subunit alpha2delta 2, CASVDD
External IDsOMIM: 607082; MGI: 1929813; HomoloGene: 4400; GeneCards: CACNA2D2; OMA:CACNA2D2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001005505
NM_001174051
NM_001291101
NM_006030

NM_001174047
NM_001174048
NM_001174049
NM_001174050
NM_020263

RefSeq (protein)

NP_001005505
NP_001167522
NP_001278030
NP_006021

NP_001167518
NP_001167519
NP_001167520
NP_001167521
NP_064659

Location (UCSC)Chr 3: 50.36 – 50.5 MbChr 9: 107.28 – 107.41 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Voltage-dependent calcium channel subunit alpha2delta-2 is a protein that in humans is encoded by the CACNA2D2 gene.[5]

This gene encodes a member of the alpha-2/delta subunit family, a protein in the voltage-dependent calcium channel complex. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization and consist of a complex of alpha-1, alpha-2/delta, beta, and gamma subunits in a 1:1:1:1 ratio. Various versions of each of these subunits exist, either expressed from similar genes or the result of alternative splicing. Research on a highly similar protein in rabbit suggests the protein described in this record is cleaved into alpha-2 and delta subunits. Alternate transcriptional splice variants of this gene, encoding different isoforms, have been characterized.[5]

CACNA2D2 containing channels are blocked by amiodarone.[6]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000007402Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000010066Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2".
  6. ^ "Amiodarone". Drugbank. Retrieved 2019-05-28.